(Q28299838)

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206430-000000000-00000

The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS

21 January 2018

1 reference

12 December 2020

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

1 reference

12 December 2020

Combination therapy in multiple sclerosis

1 reference

12 December 2020

The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

1 reference

12 December 2020

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison

1 reference

12 December 2020

Disease-modifying therapy in multiple sclerosis: update and clinical implications

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

1 reference

12 December 2020

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

1 reference

12 December 2020

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

1 reference

12 December 2020

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

1 reference

12 December 2020

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

1 reference

12 December 2020

Black holes in multiple sclerosis: definition, evolution, and clinical correlations.

1 reference

12 December 2020

The epidemiology of multiple sclerosis in Europe.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Pharmacological treatment of early multiple sclerosis

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

1 reference

12 December 2020

Management of secondary-progressive multiple sclerosis

1 reference

12 December 2020

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

1 reference

12 December 2020

Interferon-beta-1b: in newly emerging multiple sclerosis

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

12 December 2020

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

1 reference

12 December 2020

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

1 reference

12 December 2020

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

1 reference

12 December 2020

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

12 December 2020

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

12 December 2020

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

1 reference

12 December 2020

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

1 reference

12 December 2020

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

1 reference

12 December 2020

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Oral therapy for multiple sclerosis--sea change or incremental step?

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

1 reference

12 December 2020

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Primary progressive multiple sclerosis : current and future treatment options

1 reference

12 December 2020

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

1 reference

12 December 2020

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020